Chinese team aims to put ‘smart’ diabetes probiotic on US shelves within 2 years

A team of Chinese researchers intends to make a 'smart' probiotic treatment for diabetes available on United States shelves within two years. This development follows experimental testing involving the administration of glucose-sensing probiotics to mice and monkeys, where the treatment functioned to regulate blood sugar levels.

Scientific findings published in Nature and Bioengineer.org detail the mechanism of these glucose-responsive probiotics, which modulate glycaemic levels in non-human subjects. Coverage from the South China Morning Post, Asia News Network, and the Borneo Bulletin notes the transition of this research from laboratory-based glycaemic modulation toward a commercial application.

While the project goals focus on a two-year timeline for market entry, the process for regulatory approval remains unaddressed in the available information. Coverage does not yet specify the clinical trial requirements or the specific pathway needed to move the treatment from animal models to human healthcare settings.